Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors

Leonardo Ferrari, Silvia Della Torre, Paola Collini, Antonia Martinetti, Giuseppe Procopio, Sara De Dosso, Roberto Bajetta, Laura Catena, Emilio Bajetta

Research output: Contribution to journalArticle

Abstract

Aims and background: Kit protein expression seems to be associated with a poor outcome in cancer patients and may be an important target for new anticancer drugs. We examined by immunohistochemistry the presence of Kit protein in neuroendocrine tumors (NETs) to explore its relationship with histological grade and proliferation index. Patients and methods: Thirty-five tumor specimens from patients with 24 well differentiated and 11 poorly differentiated NETs were examined for the presence of Kit protein and the proliferation index marker Ki-67. Results: Eleven specimens were positive for Kit protein expression, 8 of which had poorly-differentiated histology and only 3 had well-differentiated histology. Most of the tumors showing immunopositivity for Kit protein were also characterized by a high proliferation index. Conclusions: Immunohistochemical positivity for Kit protein is mainly related to poorly differentiated NETs. In our study, the percentage of tumors with immunopositivity for Kit protein was lower than that observed by other authors. This difference could be attributable to the different immunohistochemistry procedures used and to the biological heterogeneity of NETs. The number of Kit protein-positive NETs may justify targeted therapy with a tyrosine kinase receptor-associated inhibitor only in a selected subset of patients, whenever no other therapy is available and an autocrine loop sustained by the Kit receptor and its specific ligand has been demonstrated.

Original languageEnglish
Pages (from-to)531-535
Number of pages5
JournalTumori
Volume92
Issue number6
Publication statusPublished - Nov 2006

Fingerprint

Neuroendocrine Tumors
Proteins
Neoplasms
Histology
Immunohistochemistry
Receptor Protein-Tyrosine Kinases
Ligands
Therapeutics
Pharmaceutical Preparations

Keywords

  • CD117
  • Ki-67
  • Kit protein
  • Neuroendocrine tumors
  • Proliferation index

ASJC Scopus subject areas

  • Cancer Research

Cite this

Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. / Ferrari, Leonardo; Della Torre, Silvia; Collini, Paola; Martinetti, Antonia; Procopio, Giuseppe; De Dosso, Sara; Bajetta, Roberto; Catena, Laura; Bajetta, Emilio.

In: Tumori, Vol. 92, No. 6, 11.2006, p. 531-535.

Research output: Contribution to journalArticle

Ferrari, L, Della Torre, S, Collini, P, Martinetti, A, Procopio, G, De Dosso, S, Bajetta, R, Catena, L & Bajetta, E 2006, 'Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors', Tumori, vol. 92, no. 6, pp. 531-535.
Ferrari, Leonardo ; Della Torre, Silvia ; Collini, Paola ; Martinetti, Antonia ; Procopio, Giuseppe ; De Dosso, Sara ; Bajetta, Roberto ; Catena, Laura ; Bajetta, Emilio. / Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. In: Tumori. 2006 ; Vol. 92, No. 6. pp. 531-535.
@article{2e6ebdd3bafe4e438ae2dfad7641e70c,
title = "Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors",
abstract = "Aims and background: Kit protein expression seems to be associated with a poor outcome in cancer patients and may be an important target for new anticancer drugs. We examined by immunohistochemistry the presence of Kit protein in neuroendocrine tumors (NETs) to explore its relationship with histological grade and proliferation index. Patients and methods: Thirty-five tumor specimens from patients with 24 well differentiated and 11 poorly differentiated NETs were examined for the presence of Kit protein and the proliferation index marker Ki-67. Results: Eleven specimens were positive for Kit protein expression, 8 of which had poorly-differentiated histology and only 3 had well-differentiated histology. Most of the tumors showing immunopositivity for Kit protein were also characterized by a high proliferation index. Conclusions: Immunohistochemical positivity for Kit protein is mainly related to poorly differentiated NETs. In our study, the percentage of tumors with immunopositivity for Kit protein was lower than that observed by other authors. This difference could be attributable to the different immunohistochemistry procedures used and to the biological heterogeneity of NETs. The number of Kit protein-positive NETs may justify targeted therapy with a tyrosine kinase receptor-associated inhibitor only in a selected subset of patients, whenever no other therapy is available and an autocrine loop sustained by the Kit receptor and its specific ligand has been demonstrated.",
keywords = "CD117, Ki-67, Kit protein, Neuroendocrine tumors, Proliferation index",
author = "Leonardo Ferrari and {Della Torre}, Silvia and Paola Collini and Antonia Martinetti and Giuseppe Procopio and {De Dosso}, Sara and Roberto Bajetta and Laura Catena and Emilio Bajetta",
year = "2006",
month = "11",
language = "English",
volume = "92",
pages = "531--535",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors

AU - Ferrari, Leonardo

AU - Della Torre, Silvia

AU - Collini, Paola

AU - Martinetti, Antonia

AU - Procopio, Giuseppe

AU - De Dosso, Sara

AU - Bajetta, Roberto

AU - Catena, Laura

AU - Bajetta, Emilio

PY - 2006/11

Y1 - 2006/11

N2 - Aims and background: Kit protein expression seems to be associated with a poor outcome in cancer patients and may be an important target for new anticancer drugs. We examined by immunohistochemistry the presence of Kit protein in neuroendocrine tumors (NETs) to explore its relationship with histological grade and proliferation index. Patients and methods: Thirty-five tumor specimens from patients with 24 well differentiated and 11 poorly differentiated NETs were examined for the presence of Kit protein and the proliferation index marker Ki-67. Results: Eleven specimens were positive for Kit protein expression, 8 of which had poorly-differentiated histology and only 3 had well-differentiated histology. Most of the tumors showing immunopositivity for Kit protein were also characterized by a high proliferation index. Conclusions: Immunohistochemical positivity for Kit protein is mainly related to poorly differentiated NETs. In our study, the percentage of tumors with immunopositivity for Kit protein was lower than that observed by other authors. This difference could be attributable to the different immunohistochemistry procedures used and to the biological heterogeneity of NETs. The number of Kit protein-positive NETs may justify targeted therapy with a tyrosine kinase receptor-associated inhibitor only in a selected subset of patients, whenever no other therapy is available and an autocrine loop sustained by the Kit receptor and its specific ligand has been demonstrated.

AB - Aims and background: Kit protein expression seems to be associated with a poor outcome in cancer patients and may be an important target for new anticancer drugs. We examined by immunohistochemistry the presence of Kit protein in neuroendocrine tumors (NETs) to explore its relationship with histological grade and proliferation index. Patients and methods: Thirty-five tumor specimens from patients with 24 well differentiated and 11 poorly differentiated NETs were examined for the presence of Kit protein and the proliferation index marker Ki-67. Results: Eleven specimens were positive for Kit protein expression, 8 of which had poorly-differentiated histology and only 3 had well-differentiated histology. Most of the tumors showing immunopositivity for Kit protein were also characterized by a high proliferation index. Conclusions: Immunohistochemical positivity for Kit protein is mainly related to poorly differentiated NETs. In our study, the percentage of tumors with immunopositivity for Kit protein was lower than that observed by other authors. This difference could be attributable to the different immunohistochemistry procedures used and to the biological heterogeneity of NETs. The number of Kit protein-positive NETs may justify targeted therapy with a tyrosine kinase receptor-associated inhibitor only in a selected subset of patients, whenever no other therapy is available and an autocrine loop sustained by the Kit receptor and its specific ligand has been demonstrated.

KW - CD117

KW - Ki-67

KW - Kit protein

KW - Neuroendocrine tumors

KW - Proliferation index

UR - http://www.scopus.com/inward/record.url?scp=33846477327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846477327&partnerID=8YFLogxK

M3 - Article

C2 - 17260495

AN - SCOPUS:33846477327

VL - 92

SP - 531

EP - 535

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -